| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
pIC50: ~8 (FAAH)[1]
FAAH is the primary target. However, JP104 has a distinct off-target profile; it also inhibits carboxylesterase 6 (CE6) with an IC50 of approximately 50 nM. This distinguishes it from other carbamate inhibitors like URB597, which has an IC50 of ~200 nM for CE6, making it useful for studying the role of CE6 in metabolism. |
|---|---|
| ln Vitro |
JP104 is a potent irreversible inhibitor of human recombinant FAAH, with an IC50 of 7.3 nM when tested using radiolabeled oleamide as the substrate. It exhibits a pIC50 of approximately 8 against the enzyme. The alkyl derivative on JP104 can be reacted with azide-modified reporter tags for visualization of JP104 bound to FAAH in vivo.
|
| ln Vivo |
JP104 is used in vivo to visualize FAAH binding. Mice are treated with JP104, and after sacrifice, their tissues are removed. Through click chemistry, the bound probe is conjugated to a fluorescent tag, allowing for visualization of FAAH activity and localization in the tissue, or to a biotin tag for enrichment and proteomic analysis of off-targets.
|
| Enzyme Assay |
The non-cellular activity of JP104 is measured using a standard FAAH inhibition assay. Human recombinant FAAH is pre-incubated with varying concentrations of JP104 (0.001-100 uM) in a reaction buffer. Following pre-incubation, a substrate, such as radiolabeled oleamide or the fluorogenic substrate arachidonoyl-7-amino-4-methylcoumarin amide, is added. IC50 values are calculated from the residual enzyme activity.
|
| Cell Assay |
Cell-based assays are not the primary use for JP104, as it is an activity-based probe. In an ex vivo cellular context, cells or tissue lysates can be treated with JP104. After labeling, the proteins are denatured, and the biotinylated JP104 (when conjugated to a biotin tag) can be captured on streptavidin beads for subsequent Western blot or mass spectrometry analysis.
|
| Animal Protocol |
A common in vivo protocol involves treating wild-type and FAAH-/- mice with JP104. Mice are administered JP104 (typically intraperitoneally). After a specified time (e.g., 1 hour), the animals are euthanized, and brains and livers are collected. Tissue lysates are then prepared and subjected to click chemistry conjugation with a rhodamine-azide tag for in-gel fluorescence scanning.
|
| ADME/Pharmacokinetics |
JP104 does not have traditional PK parameters, as it is an activity-based probe. Its “pharmacokinetics” relate to its ability to irreversibly bind to its targets. It has a long residence time on the target. It is used for activity-based protein profiling (ABPP) in mice, where its binding to targets is visualized hours after administration.
|
| Toxicity/Toxicokinetics |
As an irreversible carbamate inhibitor, toxicity concerns relate to its off-target binding. Unlike URB597, JP104 has a distinct off-target inhibition of carboxylesterase 6 (CE6), an enzyme involved in drug metabolism and lipid homeostasis. This off-target activity is an important consideration when using JP104 in metabolic studies.
|
| References | |
| Additional Infomation |
JP104 is distinguished from other FAAH inhibitors (like PF-3845 or URB597) by its unique off-target profile, particularly its strong inhibition of CE6. This makes it a powerful tool for the CE6 research community. The ability to conjugate it to azide-modified tags (e.g., azido-rhodamine) via click chemistry makes it a versatile probe for both in vivo and ex vivo visualization of enzyme activity.
|
| Molecular Formula |
C25H30N2O3
|
|---|---|
| Molecular Weight |
406.52
|
| Exact Mass |
410.256
|
| CAS # |
887264-45-1
|
| PubChem CID |
24860363
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
565.9±50.0 °C at 760 mmHg
|
| Flash Point |
296.0±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
6.76
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
30
|
| Complexity |
568
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C#CCCCCCCCCCNC(OC1=CC=CC(C2=CC(C(N)=O)=CC=C2)=C1)=O
|
| InChi Key |
BCKBOXGAYIOHDQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H30N2O3/c1-2-3-4-5-6-7-8-9-10-17-27-25(29)30-23-16-12-14-21(19-23)20-13-11-15-22(18-20)24(26)28/h1,11-16,18-19H,3-10,17H2,(H2,26,28)(H,27,29)
|
| Chemical Name |
[3-(3-carbamoylphenyl)phenyl] N-undec-10-ynylcarbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4599 mL | 12.2995 mL | 24.5990 mL | |
| 5 mM | 0.4920 mL | 2.4599 mL | 4.9198 mL | |
| 10 mM | 0.2460 mL | 1.2300 mL | 2.4599 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
